CareLit Fachartikel

The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer

C Mayer, M Schmidt, EM Grischke, G Gebauer, HC Fricke, F Lenz, E Bischofs, M Wallwiener, F Marme, A Schneeweiss, C Sohn, M Eichbaum, J Rom · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10

Dokument
1023038
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Geburtshilfe und Frauenheilkunde
Autor:innen
C Mayer, M Schmidt, EM Grischke, G Gebauer, HC Fricke, F Lenz, E Bischofs, M Wallwiener, F Marme, A Schneeweiss, C Sohn, M Eichbaum, J Rom
Ausgabe
Heft 10 / 2016
Seiten
–
Erschienen: 2016-10-13 00:00:00
ISSN
0016-5751
DOI
10.1055/s-0036-1592664

Zusammenfassung

Background: A combined therapy consisting of the investigational anti-VEGFR tyrosine kinase inhibitor pazopanib (GW786034, paz) and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent platinum-resistant epithelial ovarian cancer (EOC). Methods: This study was designed as a multicenter phase I trial evaluating the optimal dose for paz as well as activity and tolerability of a combination regimen consisting of paz and metronomic cyclophosphamide 50 mg daily p.o. in monthly cycles. Patients with histologically proven recurrent platinum-resistant EOC were included.…

Schlagworte

Geburtshilfe und Frauenheilkunde